Skip to main content
. 2010 Jul 9;37(Suppl 1):104–113. doi: 10.1007/s00259-010-1499-9

Fig. 3.

Fig. 3

a Biodistribution of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]2 and 111In-DOTA-E{E[c(RGDfK)]2}2 at 8 h p.i. in athymic mice with s.c. SK-RC-52 tumours (5 mice/group). b Tumour to blood ratios of 111In-DOTA-E-c(RGDfK), 111In-DOTA-E-[c(RGDfK)]2 and 111In-DOTA-E{E[c(RGDfK)]2}2 at 2, 8 and 24 h after injection in athymic mice with s.c. SK-RC-52 tumours. Each bar represents the mean values ± SD. Values were analysed using one-way analysis of variance, *p < 0.05